"We are excited to present new clinical and preclinical data at this year's AACRAnnual Meeting" said George Chen, Founder, Chairman and Chief Executive Officer of D3 Bio.
ACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study, showed potent preclinical synergy with Topoisomerase 1 (Topo 1) inhibitors, commonly used payloads in antibody-drug conjugates (ADCs) ... .
Four presentations deliver new insights into zanidatamab, including its differentiated HER2 biology. Four presentations deliver new insights into zanidatamab, including its differentiated HER2 biology ... .